Genomtec S.A. (GMT) - Total Liabilities
Based on the latest financial reports, Genomtec S.A. (GMT) has total liabilities worth zł6.01 Million PLN (≈ $1.65 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Genomtec S.A.'s assets to evaluate the company's liquid asset resilience ratio.
Genomtec S.A. - Total Liabilities Trend (2019–2024)
This chart illustrates how Genomtec S.A.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Genomtec S.A. assets under control.
Genomtec S.A. Competitors by Total Liabilities
The table below lists competitors of Genomtec S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Enerside Energy S.A.
MC:ENRS
|
Spain | €83.98 Million |
|
OXE Marine AB
ST:OXE
|
Sweden | Skr163.98 Million |
|
Blue Energy Ltd
AU:BLU
|
Australia | AU$1.19 Million |
|
Volt Power Group Ltd
AU:VPR
|
Australia | AU$1.81 Million |
|
Sab Events & Governance Now Media Limited
NSE:SABEVENTS
|
India | Rs32.97 Million |
|
ZincX Resources Corp
V:ZNX
|
Canada | CA$1.90 Million |
|
Lode Resources Ltd
AU:LDR
|
Australia | AU$1.66 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Genomtec S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Genomtec S.A.'s balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genomtec S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genomtec S.A. (2019–2024)
The table below shows the annual total liabilities of Genomtec S.A. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | zł9.44 Million ≈ $2.60 Million |
+23.09% |
| 2023-12-31 | zł7.67 Million ≈ $2.11 Million |
+11.68% |
| 2022-12-31 | zł6.87 Million ≈ $1.89 Million |
+97.47% |
| 2021-12-31 | zł3.48 Million ≈ $957.20K |
+93.33% |
| 2020-12-31 | zł1.80 Million ≈ $495.11K |
-0.13% |
| 2019-12-31 | zł1.80 Million ≈ $495.77K |
-- |
About Genomtec S.A.
Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. The company's flagship project is the Genomtec ID, a diagnostic platform that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analysi… Read more